Paloma Partners Management Co purchased a new stake in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,903 shares of the company’s stock, valued at approximately $452,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of PCRX. First Republic Investment Management Inc. acquired a new stake in Pacira Pharmaceuticals in the 4th quarter valued at $201,000. Bouchey Financial Group Ltd acquired a new stake in Pacira Pharmaceuticals in the 4th quarter valued at $205,000. Twin Focus Capital Partners LLC acquired a new stake in Pacira Pharmaceuticals in the 4th quarter valued at $206,000. Fisher Asset Management LLC acquired a new stake in Pacira Pharmaceuticals in the 4th quarter valued at $241,000. Finally, Amalgamated Bank acquired a new stake in Pacira Pharmaceuticals in the 4th quarter valued at $244,000.
In related news, CEO David M. Stack sold 28,885 shares of the business’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total value of $1,160,888.15. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.60% of the stock is currently owned by insiders.
A number of research firms have issued reports on PCRX. Oppenheimer reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, March 1st. Royal Bank of Canada set a $44.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 1st. Wedbush reaffirmed a “buy” rating on shares of Pacira Pharmaceuticals in a report on Friday, January 5th. BidaskClub raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Finally, Mizuho cut their price objective on shares of Pacira Pharmaceuticals from $44.00 to $31.00 and set a “neutral” rating on the stock in a report on Wednesday. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $44.06.
PCRX stock opened at $32.30 on Friday. The company has a quick ratio of 6.22, a current ratio of 6.96 and a debt-to-equity ratio of 0.99. The firm has a market cap of $1,302.78, a PE ratio of -29.63 and a beta of 1.95. Pacira Pharmaceuticals Inc has a fifty-two week low of $27.80 and a fifty-two week high of $52.47.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.46. The company had revenue of $79.08 million for the quarter, compared to the consensus estimate of $79.06 million. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.09 EPS. analysts predict that Pacira Pharmaceuticals Inc will post -0.59 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Paloma Partners Management Co Purchases New Stake in Pacira Pharmaceuticals Inc (PCRX)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2018/03/24/paloma-partners-management-co-purchases-new-stake-in-pacira-pharmaceuticals-inc-pcrx.html.
Pacira Pharmaceuticals Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.